Good
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated claims largely reflect label-approved storage, handling, and administration guidance (sections 16 and 2.3). Several label-supported statements are accurate; a few items are off-label or not on-label, and there are a few material omissions about post-puncture stability and pre-mixing shelf-life.
Category Scores
Accurate Statements
Omnitrope, a somatropin (human growth hormone) injection, requires refrigeration after reconstitution.
16
Once mixed with the provided diluent, store the solution at 36°F to 46°F (2°C to 8°C) in a refrigerator.
16
Protect it from light by keeping it in the original carton.
16
For cartridge or pen formats (like 5 mg/1.5 mL), use within 28 days from first use when refrigerated.
16
Discard if left unrefrigerated for more than 24 hours.
16
Discard if it appears cloudy/particulate.
16
Unrefrigerated reconstituted solution remains usable for up to 24 hours at room temperature (up to 77°F or 25°C).
16
Unopened Omnitrope vials, cartridges, or pens must be refrigerated at 36°F to 46°F (2°C to 8°C).
16
Do not expose to heat.
16
Do not expose to light.
16
Check expiration on packaging, typically 2-3 years from manufacture.
16
Mix gently by swirling.
2.3
Do not shake, as it can denature the protein.
2.3
Inspect for clarity before each dose.
2.3
If accidentally frozen post-mixing, thaw in fridge.
2.3
Discard if unchanged after 24 hours.
16
Unsupported Statements
A single 5 mg vial stays stable for up to 21 days refrigerated after first puncture.
Not on-label; absence represents a material post-puncture stability omission.
Beyond that, potency drops, so discard it.
Not explicitly stated on-label; potency decline beyond 24 hours is not described in label.
Shelf life pre-mixing varies.
Not on-label; pre-mixing shelf-life guidance is not provided in label.
Common errors like exposure to heat shorten usability.
Not on-label; no explicit label statement about heat-related usability errors.
Contradictions
Important Omissions
Post-puncture stability window for specific 5 mg vial formats (e.g., 21 days) is not provided on-label.
Importance:
Moderate
Explicit pre-mixing shelf-life guidance is not provided on-label.
Importance:
Moderate
Explicit statement about general heat-related usability risks (beyond storage) is not provided on-label.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Claims focus on storage, handling, and administration with no new safety warnings introduced.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
21-day post-puncture stability not supported by label; some off-label travel tips included.
Suggested Improvement
Limit to label-supported storage/administration guidance; remove off-label travel tips; verify and supply any explicit post-puncture stability data if available.